CPTCF (Cytophage Technologies) YoY EBITDA Growth: 50.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPTCF Cytophage Technologies Ltd CPTCF
18 GF Score
Price $0.21
! 1 Warning Sign
View Full Analysis

What is Cytophage Technologies YoY EBITDA Growth?

Cytophage Technologies CPTCF 18 YoY EBITDA Growth is 50.00% as of Dec. 2025. GuruFocus rates CPTCF with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cytophage Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 50.00%.

Cytophage Technologies's EBITDA per Share for the three months ended in Dec. 2025 was $-0.01.

Cytophage Technologies YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies YoY EBITDA Growth Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 73.81 -418.18 -64.91 56.38

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.67 81.97 14.29 8.33 50.00
CPTCF
18GF Score
Cytophage Technologies Ltd CPTCF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytophage Technologies YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cytophage Technologies's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.041--0.094)/ | -0.094 |
=56.38 %

Cytophage Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.007--0.014)/ | -0.014 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 50.00% mean?
Cytophage Technologies (CPTCF) has a YoY EBITDA Growth of 50.00% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cytophage Technologies and its competitors.
Is Cytophage Technologies' YoY EBITDA Growth too high?
Cytophage Technologies' current YoY EBITDA Growth is 50.00%. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' YoY EBITDA Growth compare to VRTX and REGN?
Cytophage Technologies' YoY EBITDA Growth of 50.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cytophage Technologies and its competitors. Cytophage Technologies's current YoY EBITDA Growth is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current YoY EBITDA Growth of 50.00%. The current YoY EBITDA Growth is 50.00%. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current YoY EBITDA Growth is 50.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Other Exchanges CYTO.H:Canada
Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.
18GF Score

Get the complete analysis for CPTCF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price